Chemotherapy of Leprosy

Cochrane, R. G.

doi:10.1136/bmj.2.4796.1220

Cited by 15 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…51 After the clinical trials on glucosulfone sodium had been reported, investigations into the value of dapsone revealed that it was as effective as any of the sulfones derived from it for treating leprosy. 52 Despite problems with resistance, it remains in use today as the standard antileprotic sulfone, while its analogues have been largely abandoned.…”

Section: Antileprotic Drugsmentioning

confidence: 99%

Drugs Originating from the Screening of Dyes

Sneader

2005

Drug Discovery

View full text Add to dashboard Cite

Section: Antileprotic Drugsmentioning

confidence: 99%

Drugs Originating from the Screening of Dyes

Sneader

2005

Drug Discovery

View full text Add to dashboard Cite

“…The response of Case 2 to thiosemicarbazone has been good, and the gratifying absence of toxic side-effects supports Ryrie's (1950) views on the use of this drug. Nevertheless, many years must elapse before the question of "cure" by this or any other chemotherapeutic method can be assessed (Cochrane, 1952).…”

Section: Commentmentioning

confidence: 99%

Leprosy: Report on Four Cases

Rogers¹,

Adamson²

1953

BMJ

View full text Add to dashboard Cite

PYRIMETHAMINE IN VIVAX MALARIA BErim 259and the white-cell count 2,000 (polymorphs 22%, lymphocytes 70%). The patient was given one litre of blood intravenously and was treated with penicillin, crude liver extract, and pentnucleotide. Under this regime his condition progressively improved, and 15 days after the first rise of temperature the white-cell count had returned to normal. A sternal puncture specimen taken on the eighth day of his illness showed maturation arrest of the granulocytes. It was at first thought that in the case of this individual the dosage of pyrimethamine administered (250 mg. in five days) had exceeded the limit of tolerance. He had been in the hospital for over 12 months and had received no previous treatment likely to give rise to such a syndrome. However, in the 36th week after the infective feed he experienced a malarial relapse attended with profuse epistaxis and leucopenia. The clinical picture, though considerably less severe, resembled that observed in the previous attack. Malaria parasites were seen in the peripheral blood, though in very scanty numbers. The only antimalarial drug given on this occasion was quinine (5 gr. (0.32 g.) thrice daily for 10 days).The.patient had had no pyrimethamine since his primary attack except the eight-weeks course of 25 mg. weekly which was completed three months before his relapse. It seems probable that his symptoms were attributable rather to an abnormal susceptibility to this strain of malaria parasite rather than to any effect of the drug. None of the other patients in this series (three of whom underwent a second five-day course of 50 mg. of pyrimethamine daily during their first relapse) showed any ill-effect from taking the drug, nor was there any abnormal feature in their blood count. SummaryTwelve patients suffering from primary attacks of mosquito-induced vivax malaria (Madagascar strain) were treated with 50 mg. of pyrimethamine daily for five days. The clinical response to the action of the drug was slow, and for this reason alone we regard it as unsuitable for treatment of the clinical attack in nonimmune subjects.Four of the patients relapsed between the 55th and 99th days after completing the course, one of them on two occasions.On the 99th day 11 of the group were given a single dose of 25 mg. of pyrimethamine, which wag repeated at weekly intervals for the following seven weeks. All of them relapsed on one or more occasions between the 8th and 18th weeks after completing this eight-weeks course.There is no indication that either of the two courses of pyrimethamine administered in this trial (50 mg. daily for five days during the primary attack and 25 mg. weekly for eight weeks, starting three and a half months later) were of any value in preventing the incidence of relapse, though it is possible that the attacks might have occurred somewhat earlier had the drug not been given.

show abstract

“…Cochrane (4) does not believe the thiosemicarbazones are as effective as the sulphones but should be used as a second line of attack. Lowe(S) treated several large groups with the drug, with satisfactory results.…”

mentioning

confidence: 99%

The Treatment of Leprosy With Thiosemicarbazone

Morris¹

1954

Leprosy Review

View full text Add to dashboard Cite

Chemotherapy of Leprosy

Cited by 15 publications

References 5 publications

Drugs Originating from the Screening of Dyes

Drugs Originating from the Screening of Dyes

Leprosy: Report on Four Cases

The Treatment of Leprosy With Thiosemicarbazone

Contact Info

Product

Resources

About